Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma

Abstract

Differential expression of fucosylated glycoproteins has been correlated with malignancy and metastatic potential in various types of neoplasia. Utilizing glycoproteomics techniques, changes in fucosylated serum peptides associated with naturally occurring canine lymphoma and transitional cell carcinoma (TCC) have been evaluated. In both types of neoplasia, the majority of the fucosylated peptides that changed increased with the cancer. In one lymphoma case that was examined over the course of the disease, the same fucosylated peptides that increased during pre-chemotherapy decreased during post-chemotherapy, and then subsequently increased upon recurrence of the lymphoma. When comparing all the fucosylated peptides that increased in both types of cancer, there were only two peptides in common allowing discrimination between lymphoma and TCC based on their peptide profiles. These results emphasize the prospect of glycopeptide profiling in proteomics for use in discovering a panel of non-invasive, diagnostic or prognostic biomarkers of cancer.

Veterinary Biomarker Discovery: Proteomic Analysis of Acute Phase Proteins

“…Furthermore, the comparison of all fucosylated peptides detected in lymphoma and TCC, revealed only two common peptides for the two different forms of cancer. The results of the study indicated the power of glycoproteomics in discriminating between fucosylation of specific glycopeptides in two different types of cancer in dogs (Wilson et al, 2008). Modulation in the glycosylation of the APP HPT in serum from dogs with several diseases including anaemia, inflammation, lymphoma, and chronic progressive hepatitis has also been reported (Anderssen et al, 2001).…”

“…In veterinary research, differential expression and increased abundance of fucosylated peptides have been reported for lymphoma and transitional cell carcinoma (TCC) in dogs (Wilson et al, 2008). The progression of canine lymphoma was monitored during the course of disease, and it was discovered that the same fucosylated peptides that increased during the pre-chemotherapy period were reduced post-chemotherapy treatments.…”

“…Though APPs have been characterized as non-specific responders to pro-inflammatory signals, differences in APP expression during disease across species have been reported, and evidence exists that circulating concentrations of APPs in blood and other biological fluids are a direct indication of disease severity (Eckersall and Bell, 2010;Gruys et al, 2005;Murata et al, 2004). Additionally, more recent data based on the proteomic analyses of APPs during disease suggests that modification of glycoproteins could be disease specific (Wilson et al, 2008). The prospect of using APPs as biomarkers of inflammation and infection for veterinary applications has inspired a significant body of research, including the development of antibodies and other quantitative methods for analyzing APP expression during disease in food animal species (Murata et al, 2004).…”

Proteomics in Veterinary Medicine

“…Glycoproteomic profile of serum peptides has been examined by a combination of lectin affinity selection, global internal standard technology, high-performance LC, and MALDI-TOF to investigate canine lymphoma and transitional cell carcinoma. 115 Two peptides were identified that allowed discrimination between these conditions.…”

Application of post-genomic techniques in dog cancer research

“…86 Briefly, tryptic peptides were generated from serum samples of healthy and lymphoma-affected dogs. 87 Primary amines on peptides were then acylated with GIST isotope labelling reagents, and fucosylated peptides sorted by lectin binding affinity chromatography. After deglycosylation and fractionation, peptides were analysed and quantified with MALDI-TOF.…”